253 related articles for article (PubMed ID: 36086826)
21. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
[TBL] [Abstract][Full Text] [Related]
22. Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
Li D; Sun FF; Wang D; Wang T; Peng JJ; Feng JQ; Li H; Wang C; Zhou DJ; Luo H; Fu ZQ; Zhang T
Oncol Res; 2020 Dec; 28(5):467-481. PubMed ID: 32560747
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression.
Fu Y; Mackowiak B; Feng D; Lu H; Guan Y; Lehner T; Pan H; Wang XW; He Y; Gao B
Gut; 2023 Oct; 72(10):1942-1958. PubMed ID: 36593103
[TBL] [Abstract][Full Text] [Related]
24. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
[TBL] [Abstract][Full Text] [Related]
25. HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma.
Zhang ZS; Yang RH; Yao X; Cheng YY; Shi HX; Yao CY; Gao ZX; Qi DF; Zhang WK; Dou YY; Guo J; Hu MW; Zhao H; Fang D
Cell Biol Int; 2021 Dec; 45(12):2521-2533. PubMed ID: 34486197
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of miR-133a-3p enhances Bufothionine-induced gastric cancer cell death by modulating IGF1R/PI3K/Akt signal pathway mediated ER stress.
Hu ZH; Wang GJ; Li RX; Zhu TY; Wang ZY; Ding HX; Hu XM
Life Sci; 2020 Oct; 259():118180. PubMed ID: 32758622
[TBL] [Abstract][Full Text] [Related]
27. HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.
Zhang Y; Xu J; Zhang S; An J; Zhang J; Huang J; Jin Y
Cell Physiol Biochem; 2018; 50(6):2124-2138. PubMed ID: 30415263
[TBL] [Abstract][Full Text] [Related]
28. miR-122-3p targets UBE2I to regulate the immunosuppression of liver cancer and the intervention of Liujunzi formula.
Guo Z; Wang Y; Qin W; Heng Y; Chen X; Liu N; Li J; Wu H; Zhou Y; Zhang R; Song S; Wu Z
J Ethnopharmacol; 2024 Jul; 329():118081. PubMed ID: 38570148
[TBL] [Abstract][Full Text] [Related]
29. Catalpol inhibits cell proliferation, invasion and migration through regulating miR-22-3p/MTA3 signalling in hepatocellular carcinoma.
Zhao L; Wang Y; Liu Q
Exp Mol Pathol; 2019 Aug; 109():51-60. PubMed ID: 31145886
[TBL] [Abstract][Full Text] [Related]
30. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.
Peng L; Pan B; Zhang X; Wang Z; Qiu J; Wang X; Tang N
Cell Biol Toxicol; 2022 Dec; 38(6):1159-1173. PubMed ID: 35438468
[TBL] [Abstract][Full Text] [Related]
31. MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF-β/Smad3 signaling pathway.
Sun L; Guo Z; Sun J; Li J; Dong Z; Zhang Y; Chen J; Kan Q; Yu Z
Biomed Pharmacother; 2018 Nov; 107():168-176. PubMed ID: 30086463
[TBL] [Abstract][Full Text] [Related]
32. Upregulating microRNA-373-3p promotes apoptosis and inhibits metastasis of hepatocellular carcinoma cells.
Li H; Wang N; Xu Y; Chang X; Ke J; Yin J
Bioengineered; 2022 Jan; 13(1):1304-1319. PubMed ID: 34983307
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Roshani Asl E; Rasmi Y; Baradaran B
J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
[TBL] [Abstract][Full Text] [Related]
34. Astragalus polysaccharides decrease proliferation, migration, and invasion but increase apoptosis of human osteosarcoma cells by up-regulation of microRNA-133a.
Chu Y; Fang Y; Chi J; Li J; Zhang D; Zou Y; Wang Z
Braz J Med Biol Res; 2018 Nov; 51(12):e7665. PubMed ID: 30462772
[TBL] [Abstract][Full Text] [Related]
35. Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN-γ Signaling.
Li Z; Gao WQ; Wang P; Wang TQ; Xu WC; Zhu XY; Liu H
Curr Cancer Drug Targets; 2020; 20(11):868-874. PubMed ID: 32748749
[TBL] [Abstract][Full Text] [Related]
36. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
37. Long non-coding RNA HOTAIR promotes hepatocellular carcinoma progression by regulating miR-526b-3p/DHX33 axis.
Liu Z; Ouyang G; Lu W; Zhang H
Genes Genomics; 2021 Aug; 43(8):857-868. PubMed ID: 33843021
[TBL] [Abstract][Full Text] [Related]
38. Mifepristone inhibited tumor progression by disrupting the stability of PD-L1 by miR-127-3p/VAMP2 in ovarian cancer.
Gu Y; Zhang Y; Liu J
Pak J Pharm Sci; 2022 Jan; 35(1(Special)):393-400. PubMed ID: 35236654
[TBL] [Abstract][Full Text] [Related]
39. lncRNA KCNQ1OT1 reverses the effect of sevoflurane on hepatocellular carcinoma progression via regulating the miR-29a-3p/CBX3 axis.
Zhou W; Li H; Shang S; Liu F
Braz J Med Biol Res; 2021; 54(7):e10213. PubMed ID: 34008749
[TBL] [Abstract][Full Text] [Related]
40. [Polysaccharide of Atractylodis Macrocephalae Rhizoma inhibits expression of immune checkpoint PD-L1 by targeting miR-34a in esophageal carcinoma cells].
Han YC; Chen YL; Fan XQ; Shang YW; Chen X; Wang G; Shi B; Gao QL
Zhongguo Zhong Yao Za Zhi; 2022 Mar; 47(6):1658-1665. PubMed ID: 35347965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
